Akebia Therapeutics, Inc.
$0.90
-$0.02 (-2.43%)
$0.87Day Range$0.94
Key Statistics
Market Cap
$248.15M
Shares Outstanding
277.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 20, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$0.93
Day High
$0.94
Day Low
$0.87
Volume
8.72M
VWAP
$0.89
Prev Close
$0.92
Transactions
--
Acc. Volume
--
About Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
PHARMACEUTICAL PREPARATIONSSIC 2834194 employees245 FIRST STREET, CAMBRIDGE, MA, 02142617-871-2098IPO Mar 20, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001517022
- Composite FIGI
- BBG000R33R00
- Share Class FIGI
- BBG001T922S9
- Ticker Root
- AKBA
- SIC Code
- 2834
About Akebia Therapeutics, Inc. (AKBA) Stock
Akebia Therapeutics, Inc. (AKBA) closed the 2026-09-17 session at $0.90, down 2.43% versus the previous close (-0.02). The stock opened at $0.93 and traded between $0.87 and $0.94 during that session. Session trading volume was 8.7M shares. The volume-weighted average price (VWAP) is $0.89.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Akebia Therapeutics, Inc. has a market capitalization of $248.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AKBA is listed on the XNAS exchange. The company employs approximately 194 people. Akebia Therapeutics, Inc. is headquartered in CAMBRIDGE, MA. The recorded listing date is 2014-03-20.
On this page you can find market AKBA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.